Destiny Pharma Holdings plc (DEST) Ord GBP0.01
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Destiny Pharma reports progress on clinical assets
4 January 2024 11:27
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma said in a year-end update on Thursday that its primary focus remained on realising the full potential of its XF-73 Nasal asset.
-
Sunday share tips: Destiny Pharma, Invinity Energy Systems
29 October 2023 21:01
(Sharecast News) - The Financial Mail on Sunday's Midas column spied long-term potential in Destiny Pharma's shares.
-
Destiny Pharma loss widens as it extends cash runway
13 April 2023 14:16
(Sharecast News) - Biotechnology company Destiny Pharma reported a loss before tax of £7.7m in its 2022 results on Thursday, widening from £6.3m in the prior year.
-
Destiny Pharma upbeat on infection prevention study
4 April 2023 11:33
(Sharecast News) - Destiny Pharma said in an update on Tuesday that its novel medicine for preventing life-threatening infections, 'NTCD-M3', had been shown to colonise the gut successfully in a C...
-
Destiny publishes 'important' research on its preoperative treatment candidate
24 March 2023 15:34
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced the publication of landmark clinical data for 'XF-73' on Friday, in the US-based peer-reviewed journal Infection...
-
Destiny Pharma jumps on 2022 progress
22 December 2022 14:06
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma updated the market on its progress in 2022 on Thursday, including working to finalise a partnering agreement for 'NTCD-M3',...
-
Destiny Pharma finalises plans for next study of its lead asset
7 December 2022 16:27
(Sharecast News) - Biotechnology company Destiny Pharma has finalised plans for phase-three studies of its late-stage clinical asset 'XF-73 Nasal', it announced on Wednesday.
-
Destiny Pharma starts new safety study of dermal formulation
15 November 2022 12:53
(Sharecast News) - Biotechnology developer Destiny Pharma announced the start of an investigational new drug (IND)-enabling safety study with its novel 'XF-73 Dermal' formulation.
-
Destiny Pharma gets positive feedback from EMA on new antibiotic treatment
7 September 2022 08:06
(Sharecast News) - Clinical stage biotechnology company Destiny Pharma has received "positive feedback" from the European Medicine Agency regarding the proposed Phase III development programme of...
-
Destiny Pharma awarded Cystic Fibrosis Foundation project
12 July 2022 15:39
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has received an award from the Cystic Fibrosis Foundation, it announced on Tuesday.
-
Destiny Pharma appoints Yuri Martina as chief medical officer
3 May 2022 12:16
(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced the appointment of Dr Yuri Martina as its chief medical officer on Tuesday.
-
Destiny Pharma to raise up to £7m in discounted fundraising
8 March 2022 13:55
(Sharecast News) - Clinical stage biotechnology company Destiny Pharma said on Tuesday that it was looking to raise up to £7m in a conditional fundraising to continue progress towards Phase 3 in its two...
Company announcements Announcements
-
Posting of Annual Report and Notice of AGM
9 May 2024 14:35
Destiny Pharma
-
Full year results and review of strategic options
25 April 2024 07:00
Destiny Pharma
-
Notice of Full Year Results
8 April 2024 07:00
Destiny Pharma
-
Exercise of Options and Total Voting Rights
19 March 2024 14:47
Destiny Pharma
-
Clinical development update
31 January 2024 07:00
Destiny Pharma
-
Appointment of Nominated Adviser and Sole Broker
22 January 2024 07:00
Destiny Pharma
-
Year End Business Update
4 January 2024 07:00
Destiny Pharma
-
Grant of Share Options
20 October 2023 07:00
Destiny Pharma
-
Director/PDMR Shareholding
19 October 2023 07:00
Destiny Pharma
-
XF Pipeline Update Meeting
17 October 2023 07:01
Destiny Pharma
-
Publication of new microbiological data for XF-73
17 October 2023 07:00
Destiny Pharma
-
Director/PDMR Shareholding
10 October 2023 07:00
Destiny Pharma
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.